Radioiodine Therapy for Thyroid Cancer

Objectives of radioiodine therapy for thyroid cancer are presented, and agents, targets and treatment strategies for iodine-refractory thyroid cancer are discussed.

Course ID: Q00422 Category:
Modalities: ,

2.0

Satisfaction Guarantee

$24.00

View cart

Targeted CE per ARRT’s Discipline, Category, and Subcategory classification:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]

Nuclear Medicine Technology: 1.00
Procedures: 1.00
Endocrine and Oncology Procedures: 1.00

Outline

  1. Introduction
  2. Thyroid Cancer Pathophysiology, Radiobiology, and Demographics
  3. Current Utilization of Radioactive Iodine Therapy
  4. Patient Selection
  5. Dose Selection
  6. Iodine-Refractory Disease
  7. Options for Iodine-Refractory Disease
    1. Reinduction of Iodine Uptake
    2. Multitargeted Kinase Inhibitors
  8. Conclusion

Objectives

Upon completion of this course, students will:

  1. identify which cancer is commonly treated with radioiodine
  2. be familiar with the role of radioiodine in medullary thyroid cancer
  3. identify the differentiated thyroid cancer subtypes
  4. identify the categories of radioiodine use for thyroid cancer
  5. be familiar with criteria for patient selection for adjuvant therapy
  6. be familiar with the level of toxicity for thyroid cancer treatment
  7. be familiar with ATA guidelines for thyroid cancer patients not requiring radioiodine therapy
  8. identify the criteria for radioactive iodine therapy
  9. be familiar with the factors taken into account when selecting a radioiodine dose for therapeutic intent
  10. identify who is credited with the whole-body and blood dosimetry for radioiodine therapy
  11. identify the radioisotope of iodine that is positron emitting
  12. identify the drug approved in 2013 for use in iodine-refractory disease
  13. identify the role of selemetinib in iodine-refractory disease
  14. understand the role that sorafenib plays in the treatment of iodine-refractory disease
  15. be familiar with the disadvantages of current targeted therapeutics
  16. understand the potential 124I PET/CT may have on response to radioiodine therapy